Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

Drug Resistance Updates

Volumn 11, Issue 1-2, 2008, Pages 32-50

  LoPiccolo, Jaclyn ^a   Blumenthal, Gideon M ^a   Bernstein, Wendy B ^a   Dennis, Phillip A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Akt; Cancer; Chemotherapy; Combination; mTOR inhibitors; Perfosine; PI 103; PI3 kinase; PX 866; RAD 001; Rapamycin; Triciribine (API 2); Wortmannin

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ALPHA INTERFERON; BEVACIZUMAB; BORTEZOMIB; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PERIFOSINE; PROTEIN KINASE B; PX 866; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; TRICIRIBINE; UNINDEXED DRUG; VINBLASTINE; WORTMANNIN;

ACIDOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CHONDROSARCOMA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DYSPHAGIA; DYSPNEA; EDEMA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ESOPHAGUS CANCER; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LOADING DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MELANOMA; MOLECULAR IMAGING; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAIN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RASH; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; SOMATIC MUTATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UREMIA; VOMITING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME;

EID: 43049131769     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2007.11.003     Document Type: Review

References (233)

1. Albert J.M., Kim K.W., Cao C., and Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 5 (2006) 1183-1189
2. Ali U.I., Schriml L.M., and Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 91 (1999) 1922-1932
3. Alkan S., and Izban K.F. Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood 99 (2002) 2278-2279
4. Andjelkovic M., Alessi D.R., Meier R., et al. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272 (1997) 31515-31524
5. Argiris A., Cohen E., Karrison T., et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol. Ther. 5 (2006) 766-770
6. Asselin E., Mills G.B., and Tsang B.K. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61 (2001) 1862-1868
7. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22 (2004) 909-918
8. Aveyard J.S., Skilleter A., Habuchi T., and Knowles M.A. Somatic mutation of PTEN in bladder carcinoma. Br. J. Cancer 80 (1999) 904-908
9. Bailey H.H., Mahoney M.R., Ettinger D.S., et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 107 (2006) 2462-2467
10. Balendran A., Casamayor A., Deak M., et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr. Biol. 9 (1999) 393-404
11. Bellacosa A., de Feo D., Godwin A.K., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64 (1995) 280-285
12. Bertram J., Peacock J.W., Fazli L., et al. Loss of PTEN is associated with progression to androgen independence. Prostate 66 (2006) 895-902
13. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759
14. Bianco R., Shin I., Ritter C.A., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22 (2003) 2812-2822
15. Birle D.C., and Hedley D.W. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol. Cancer Ther. 5 (2006) 2494-2502
16. Boulay A., Rudloff J., Ye J., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 11 (2005) 5319-5328
17. Breslin E.M., White P.C., Shore A.M., Clement M., and Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br. J. Pharmacol. 144 (2005) 791-800
18. Brognard J., Sierecki E., Gao T., and Newton A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 25 (2007) 917-931
19. Buck E., Eyzaguirre A., Brown E., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 5 (2006) 2676-2684
20. Cao C., Subhawong T., Albert J.M., et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 66 (2006) 10040-10047
21. Caron R.W., Yacoub A., Li M., et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol. Cancer Ther. 4 (2005) 257-270
22. Carpenter J.T., Campone J.T., Colomer M., et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J. Clin. Oncol. ASCO Annu. Meet. Proc. 23 16S (Suppl.) (2005) 564
23. Carpten J.D., Faber A.L., Horn C., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007) 439-444
24. Catley L., Hideshima T., Chauhan D., et al. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp. Hematol. 35 (2007) 1038-1046
25. Cervera A., Nemunaitis A., Ebrahimi J.J., et al. Online Collaborative Oncology Group, perifosine (P) can be combined with docetaxel (T) without dose reduction of either drug. J. Clin. Oncol. ASCO Annu. Meet. Proc. (Part I) 24 June 20 Suppl. (2006) 13066
26. Chan C.T., Metz M.Z., and Kane S.E. Differential sensitivities of trastuzumab (herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res. Treat. 91 (2005) 187-201
27. Chan S., Scheulen M.E., Johnston S., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23 (2005) 5314-5322
28. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23 (2005) 357-361
29. Cheng J.Q., Ruggeri B., Klein W.M., et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. (USA) 93 (1996) 3636-3641
30. Chiang C.T., Way T.D., and Lin J.K. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol. Cancer Ther. 6 (2007) 2127-2138
31. Choe G., Horvath S., Cloughesy T.F., et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63 (2003) 2742-2746
32. Costa L.J., Gemmill R.M., and Drabkin H.A. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology 69 (2007) 596-602
33. Cragg M.S., Kuroda J., Puthalakath H., et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4 (2007) e316
34. Crul M., Rosing H., de Klerk G.J., et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer 38 (2002) 1615-1621
35. Dahia P.L. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer 7 (2000) 115-129
36. Dai D.L., Martinka M., and Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23 (2005) 1473-1482
37. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
38. Delcommenne M., Tan C., Gray V., Rue L., Woodgett J., and Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. (USA) 95 (1998) 11211-11216
39. Del Peso L., Gonzalez-Garcia M., Page C., Herrera R., and Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278 (1997) 687-689
40. Denlinger C.E., Rundall B.K., and Jones D.R. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. J. Thorac. Cardiovasc. Surg. 130 (2005) 1422-1429
41. Diehl J.A., Cheng M., Roussel M.F., and Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12 (1998) 3499-3511
42. Douros J., and Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev. 8 (1981) 63-87
43. Dreher T., Zentgraf H., Abel U., et al. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch. 444 (2004) 509-517
44. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 95 (2006) 1148-1154
45. Ebrahimi B., Shiffman B., Birch R., et al. Online Collaborative Oncology Group, a phase 1 study of daily oral perifosine with weekly paclitaxel. J. Clin. Oncol. ASCO Annu. Meet. Proc. (Part I) 24 Suppl. (2006) 13117
46. Edwards E., Geng L., Tan J., et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 62 (2002) 4671-4677
47. Eng C.P., Sehgal S.N., and Vezina C. Activity of rapamycin (AY-22 989) against transplanted tumors. J. Antibiot. (Tokyo) 37 (1984) 1231-1237
48. Engelman J.A., Janne P.A., Mermel C., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. (USA) 102 (2005) 3788-3793
49. Engelman J.A., Mukohara T., Zejnullahu K., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116 (2006) 2695-2706
50. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
51. Ermoian R.P., Furniss C.S., Lamborn K.R., et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 8 (2002) 1100-1106
52. Ernst D.S., Eisenhauer E., Wainman N., et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest. New Drugs 23 (2005) 569-575
53. Fan Q.W., Knight Z.A., Goldenberg D.D., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
54. Feng J., Park J., Cron P., Hess D., and Hemmings B.A. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. 279 (2004) 41189-41196
55. Festuccia C., Muzi P., Millimaggi D., et al. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr. Relat. Cancer 12 (2005) 983-998
56. Feun L.G., Blessing J.A., Barrett R.J., and Hanjani P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Am. J. Clin. Oncol. 16 (1993) 506-508
57. Feun L.G., Savaraj N., Bodey G.P., et al. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 44 (1984) 3608-3612
58. Forgacs E., Biesterveld E.J., Sekido Y., et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17 (1998) 1557-1565
59. Francis L.K., Alsayed Y., Leleu X., et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin. Cancer Res. 12 (2006) 6826-6835
60. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J. Clin. Oncol. 23 (2005) 5294-5304
61. Gayed I., Vu T., Iyer R., et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med. 45 (2004) 17-21
62. Gemmill R.M., Zhou M., Costa L., Korch C., Bukowski R.M., and Drabkin H.A. Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma. Br. J. Cancer 92 (2005) 2266-2277
63. Geoerger B., Kerr K., Tang C.B., et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61 (2001) 1527-1532
64. Gills J.J., Castillo S.S., Zhang C., et al. Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. J. Biol. Chem. 282 (2007) 27020-27029
65. Gills J.J., Holbeck S., Hollingshead M., Hewitt S.M., Kozikowski A.P., and Dennis P.A. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol. Cancer Ther. 5 (2006) 713-722
66. Goggins T.F., Shiffman T.F., Birch R., et al. Online Collaborative Oncology Group, a phase 1 study of daily oral perifosine with every 3-week paclitaxel. J. Clin. Oncol. ASCO Annu. Meet. Proc. (Part I) 24 Suppl. (2006) 13134
67. Gong Y., Somwar R., Politi K., et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4 (2007) e294
68. Gupta A.K., Cerniglia G.J., Mick R., et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int. J. Radiat. Oncol. Biol. Phys. 56 (2003) 846-853
69. Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8 (2002) 885-892
70. Haritunians T., Mori A., O'Kelly J., Luong Q.T., Giles F.J., and Koeffler H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21 (2007) 333-339
71. Harrington L.S., Findlay G.M., Gray A., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2004) 213-223
72. Hayakawa J., Ohmichi M., Tasaka K., et al. Regulation of the PRL promoter by Akt through cAMP response element binding protein. Endocrinology 143 (2002) 13-22
73. Hidalgo M., Buckner J.C., Erlichman C., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12 (2006) 5755-5763
74. Hideshima T., Catley L., Yasui H., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 (2006) 4053-4062
75. Hill M., Feng J., and Hemmings B. Identification of a plasma membrane raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr. Biol. 12 (2002) 1251
76. Hjelmeland A.B., Lattimore K.P., Fee B.E., et al. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol. Cancer Ther. 6 (2007) 2449-2457
77. Hoffman K., Holmes F.A., Fraschini G., et al. Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother. Pharmacol. 37 (1996) 254-258
78. Homicsko K., Lukashev A., and Iggo R.D. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res. 65 (2005) 6882-6890
79. Horiguchi A., Oya M., Uchida A., Marumo K., and Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J. Urol. 169 (2003) 710-713
80. Houchens D.P., Ovejera A.A., Riblet S.M., and Slagel D.E. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur. J. Cancer Clin. Oncol. 19 (1983) 799-805
81. Hsu J., Shi Y., Krajewski S., et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 98 (2001) 2853-2855
82. Hu L., Hofmann J., Lu Y., Mills G.B., and Jaffe R.B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62 (2002) 1087-1092
83. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl. J. Med. 356 (2007) 2271-2281
84. Ihle N.T., Paine-Murrieta G., Berggren M.I., et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol. Cancer Ther. 4 (2005) 1349-1357
85. Irie H.Y., Pearline R.V., Grueneberg D., et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 171 (2005) 1023-1034
86. Ito D., Fujimoto K., Mori T., et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer 118 (2006) 2337-2343
87. Janmaat M.L., Kruyt F.A., Rodriguez J.A., and Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 9 (2003) 2316-2326
88. Janmaat M.L., Rodriguez J.A., Gallegos-Ruiz M., Kruyt F.A., and Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int. J. Cancer 118 (2006) 209-214
89. Jimenez C., Jones D.R., Rodriguez-Viciana P., et al. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. 17 (1998) 743-753
90. Jimeno A., Kulesza P., Wheelhouse J., et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br. J. Cancer 96 (2007) 952-959
91. Kanamori Y., Kigawa J., Itamochi H., et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. 7 (2001) 892-895
92. Kasukabe T., Okabe-Kado J., Kato N., Sassa T., and Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res. 7 (2005) R1097-R1110
93. Kim K.W., Mutter R.W., Cao C., et al. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J. Biol. Chem. 281 (2006) 36883-36890
94. Klejman A., Rushen L., Morrione A., Slupianek A., and Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21 (2002) 5868-5876
95. Knowling M., Blackstein M., Tozer R., et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest. New Drugs 24 (2006) 435-439
96. Kohno T., Takahashi M., Manda R., and Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 22 (1998) 152-156
97. Kokubo Y., Gemma A., Noro R., et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br. J. Cancer 92 (2005) 1711-1719
98. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., Sausville E.A., and Roy K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. 2 (2003) 1093-1103
99. Kreisberg J.I., Malik S.N., Prihoda T.J., et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 64 (2004) 5232-5236
100. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., and Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 158 (2001) 2097-2106
101. Landis-Piwowar K.R., Milacic V., Chen V., et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist. Updates 9 (2006) 263-273
102. Leary A., and Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?. Br. J. Cancer 95 (2006) 661-666
103. Leighl, N.B., Dent, S., Clemons, M., et al., 2007. A phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res. Treat. [Epub ahead of print].
104. Li D., Shimamura T., Ji H., et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12 (2007) 81-93
105. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
106. Li X., Luwor R., Lu Y., Liang K., and Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 25 (2006) 525-535
107. Liang J., Zubovitz J., Petrocelli T., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8 (2002) 1153-1160
108. Liu M., Howes A., Lesperance J., et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res. 65 (2005) 5325-5336
109. Liu T.C., Wakimoto H., Martuza R.L., and Rabkin S.D. Herpes Simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt-targeting molecular therapeutics. Clin. Cancer Res. 13 (2007) 5897-5902
110. Lu C.H., Wyszomierski S.L., Tseng L.M., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin. Cancer Res. 13 (2007) 5883-5888
111. Lun X.Q., Zhou H., Alain T., et al. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 67 (2007) 8818-8827
112. Lynch D.K., Ellis C.A., Edwards P.A., and Hiles I.D. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene 18 (1999) 8024-8032
113. Ma P.C., Schaefer E., Christensen J.G., and Salgia R. A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin. Cancer Res. 11 (2005) 2312-2319
114. Ma Y.Y., Wei S.J., Lin Y.C., et al. PIK3CA as an oncogene in cervical cancer. Oncogene 19 (2000) 2739-2744
115. Mabuchi S., Ohmichi M., Kimura A., et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J. Biol. Chem. 277 (2002) 33490-33500
116. Madhunapantula S.V., Sharma A., and Robertson G.P. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 67 (2007) 3626-3636
117. Majewski N., Nogueira V., Bhaskar P., et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 16 (2004) 819-830
118. Malik S.N., Brattain M., Ghosh P.M., et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 8 (2002) 1168-1171
119. Marimpietri D., Brignole C., Nico B., et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis and angiogenesis. Clin. Cancer Res. 13 (2007) 3977-3988
120. Marimpietri D., Nico B., Vacca A., et al. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 24 (2005) 6785-6795
121. Marsh Rde W., Rocha Lima C.M., Levy D.E., et al. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol. 30 (2007) 26-31
122. Martelli A.M., Tazzari P.L., Tabellini G., et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 17 (2003) 1794-1805
123. Masiello D., Mohi M.G., McKnight N.C., et al. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol. Ther. 6 (2007) 195-201
124. Milton D.T., Riely G.J., Azzoli C.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110 (2007) 599-605
125. Min Y.H., Cheong J.W., Kim J.Y., et al. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res. 64 (2004) 5225-5231
126. Mittelman A., Casper E.S., Godwin T.A., Cassidy C., and Young C.W. Phase I study of tricyclic nucleoside phosphate. Cancer Treat. Rep. 67 (1983) 159-162
127. Mohi M.G., Boulton C., Gu T.L., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. (USA) 101 (2004) 3130-3135
128. Momota H., Nerio E., and Holland E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 65 (2005) 7429-7435
129. Moretti L., Yang E.S., Kim K.W., and Lu B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resist. Updates 10 (2007) 135-143
130. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
131. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., and Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103 (2005) 307-312
132. Nakayama H., Ikebe T., Beppu M., and Shirasuna K. High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92 (2001) 3037-3044
133. Nam S.Y., Lee H.S., Jung G.A., et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS 111 (2003) 1105-1113
134. Ng S.S., Tsao M.S., Nicklee T., and Hedley D.W. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. 7 (2001) 3269-3275
135. Ng S.S., Tsao M.S., Chow S., and Hedley D.W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60 (2000) 5451-5455
136. Nguyen D.M., Chen G.A., Reddy R., Tsai W., Schrump W.D., Cole Jr. G., and Schrump D.S. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J. Thorac. Cardiovasc. Surg. 127 (2004) 365-375
137. Nicholson K.M., and Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 14 (2002) 381-395
138. Nyakern M., Cappellini A., Mantovani I., and Martelli A.M. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol. Cancer Ther. 5 (2006) 1559-1570
139. Obenauer J.C., Cantley L.C., and Yaffe M.B. Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 31 (2003) 3635-3641
140. O'Connell M.J., Rubin J., Hahn R.G., Kvols L.K., and Moertel C.G. Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer. Cancer Treat. Rep. 71 (1987) 333-334
141. Ohta T., Ohmichi M., Hayasaka T., et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 147 (2006) 1761-1769
142. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., and Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase [see comments]. Nature 401 (1999) 82-85
143. Pacey S., Steven N., Brock C., et al. Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor everolimus (ERAD001) and gemcitabine (GEM) in patients (pts) with advanced cancers. J. Clin. Oncol. ASCO Annu. Meet. Proc. 22 Suppl. (2004) 3120
144. Paglin S., Lee N.Y., Nakar C., et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res. 65 (2005) 11061-11070
145. Perez-Tenorio G., Alkhori L., Olsson B., et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13 (2007) 3577-3584
146. Perez-Tenorio G., and Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 86 (2002) 540-545
147. Philp A.J., Campbell I.G., Leet C., et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61 (2001) 7426-7429
148. Posadas E.M., Gulley J., Arlen P.M., et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol. Ther. 4 (2005) 1133-1137
149. Puduvalli V.K., Sampath D., Bruner J.M., Nangia J., Xu R., and Kyritsis A.P. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10 (2005) 233-243
150. Punt C.J., Boni J., Bruntsch U., Peters M., and Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann. Oncol. 14 (2003) 931-937
151. Rahmani M., Reese E., Dai Y., et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 65 (2005) 2422-2432
152. Rahmani M., Yu C., Reese E., Ahmed W., Hirsch K., Dent P., and Grant S. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 22 (2003) 6231-6242
153. Raje N., Kumar S., Hideshima T., et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104 (2004) 4188-4193
154. Ramos J., Sirisawad M., Miller R., and Naumovski L. Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation. Mol. Cancer Ther. 5 (2006) 1176-1182
155. Rao R.D., Mladek A.C., Lamont J.D., et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7 (2005) 921-929
156. Rasheed B.K., Stenzel T.T., McLendon R.E., et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 57 (1997) 4187-4190
157. Reardon D.A., Quinn J.A., Vredenburgh J.J., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. 12 (2006) 860-868
158. Reis C., Giocanti N., Hennequin C., et al. A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin. Mol. Cancer Ther. 4 (2005) 1457-1464
159. Ribatti D., Nico B., Mangieri D., et al. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol. Histopathol. 22 (2007) 285-289
160. Richardson, P., Lonial, S., Jakubowiak, A., et al., 2006. A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts, 108.
161. Riely G.J., Kris M.G., Zhao B., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin. Cancer Res. 13 (2007) 5150-5155
162. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of AKT in
163. Roy H.K., Olusola B.F., Clemens D.L., et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23 (2002) 201-205
164. Ruggeri B.A., Huang L., Wood M., Cheng J.Q., and Testa J.R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinogen. 21 (1998) 81-86
165. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., and Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. 59 (1999) 2457-2463
166. Saal L.H., Johansson P., Holm K., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl. Acad. Sci. (USA) 104 (2007) 7564-7569
167. Santos S.C., Lacronique V., Bouchaert I., et al. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway. Oncogene 20 (2001) 2080-2090
168. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
169. Sarkaria J.N., Schwingler P., Schild S.E., et al. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J. Thorac. Oncol. 2 (2007) 751-757
170. Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., and Abraham R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58 (1998) 4375-4382
171. Schilcher R.B., Haas C.D., Samson M.K., Young J.D., and Baker L.H. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5′-phosphate using a weekly intravenous regimen. Cancer Res. 46 (1986) 3147-3151
172. Schlieman M.G., Fahy B.N., Ramsamooj R., Beckett L., and Bold R.J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer 89 (2003) 2110-2115
173. Sehgal S.N., Baker H., and Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28 (1975) 727-732
174. Shah O.J., Wang Z., and Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance and cell survival deficiencies. Curr. Biol. 14 (2004) 1650-1656
175. Shayesteh L., Lu Y., Kuo W.L., et al. PIK3CA is implicated as an oncogene in ovarian cancer [see comments]. Nat. Genet. 21 (1999) 99-102
176. She Q.B., Solit D., Basso A., and Moasser M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 9 (2003) 4340-4346
177. She Q.B., Solit D.B., Ye Q., O'Reilly K.E., Lobo J., and Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8 (2005) 287-297
178. Shin I., Yakes F.M., Rojo F., et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8 (2002) 1145-1152
179. Shingu T., Yamada K., Hara N., et al. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res. 63 (2003) 4044-4047
180. Shinohara E.T., Cao C., Niermann K., et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24 (2005) 5414-5422
181. Skladanowski A., Bozko P., Sabisz M., and Larsen A.K. Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle 6 (2007) 2268-2275
182. Smith J.S., Tachibana I., Passe S.M., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. 93 (2001) 1246-1256
183. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
184. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. (USA) 84 (1987) 5034-5037
185. Steinbach J.P., Eisenmann C., Klumpp A., and Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem. Biophys. Res. Commun. 321 (2004) 524-530
186. Stephan S., Datta K., Wang E., et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin. Cancer Res. 10 (2004) 6993-7000
187. Stokoe D. PTEN. Curr. Biol. 11 (2001) R502
188. Stromberg T., Dimberg A., Hammarberg A., et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103 (2004) 3138-3147
189. Sun M., Wang G., Paciga J.E., et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 159 (2001) 431-437
190. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., and Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005) 7052-7058
191. Tabellini G., Tazzari P.L., Bortul R., et al. Novel 2′-substituted, 3′-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway. Br. J. Haematol. 126 (2004) 574-582
192. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G.B., and Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 65 (2005) 3336-3346
193. Tamburini, J., Chapuis N., Bardet, V., et al., 2007. mTORC1 inhibition activates PI3K/Akt by up-regulating IGF-1R signaling in acute myeloid leukemia: rational for therapeutic inhibition of both pathways. Blood [Epub ahead of print].
194. Terakawa N., Kanamori Y., and Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr. Relat. Cancer 10 (2003) 203-208
195. Thallinger C., Poeppl W., Pratscher B., et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotransplantation model. Pharmacology 79 (2007) 207-213
196. Thallinger C., Werzowa J., Poeppl W., et al. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J. Invest. Dermatol. 127 (2007) 2411-2417
197. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12 (2006) 122-127
198. Thomson S., Buck E., Petti F., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65 (2005) 9455-9462
199. Toker A., and Newton A.C. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem. 275 (2000) 8271-8274
200. Tortora G., Bianco R., Daniele G., et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist. Updates 10 (2007) 81-100
201. Treeck O., Wackwitz B., Haus U., and Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 102 (2006) 292-299
202. Tsurutani J., Fukuoka J., Tsurutani H., et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J. Clin. Oncol. 24 (2006) 306-314
203. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., and Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9 (2007) 316-323
204. Van Meter T.E., Broaddus W.C., Cash D., and Fillmore H. Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. Cancer 107 (2006) 2446-2454
205. Van Oosterom, A., Reichardt, P., Blay, J., et al., 2005. A phase I/II trial of the oral mTOR-inhibitor eEverolimus and imatinib mesylate in patients with gastrointestinal stromal tumor (GIST) refractory to im: study update. ASCO Annual Meeting Abstract # 9033.
206. Van Ummersen L., Binger K., Volkman J., et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res. 10 (2004) 7450-7456
207. Verdu J., Buratovich M.A., Wilder E.L., and Birnbaum M.J. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat. Cell Biol. 1 (1999) 500-506
208. Vezina C., Kudelski A., and Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28 (1975) 721-726
209. Vink S.R., Lagerwerf S., Mesman E., et al. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin. Cancer Res. 12 (2006) 1615-1622
210. Vink S.R., Schellens J.H., Beijnen J.H., et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother. Oncol. 80 (2006) 207-213
211. Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., and Alessi D.R. Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. Biochem. J. 331 (1998) 299-308
212. Wang L.H., Chan J.L., and Li W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int. J. Cancer 121 (2007) 157-164
213. Wang M.Y., Lu K.V., Zhu S., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66 (2006) 7864-7869
214. Wang Q., Li N., Wang X., Kim M.M., and Evers B.M. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line. Clin. Cancer Res. 8 (2002) 1940-1947
215. Wanner K., Hipp S., Oelsner M., et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br. J. Haematol. 134 (2006) 475-484
216. Weiss S., Diaz-Lacayo M., Birch R., et al. Online Collaborative Oncology Group, a phase 1 study of daily oral perifosine and weekly gemcitabine. J. Clin. Oncol. ASCO Annu. Meet. Proc. 24 Suppl. (2006) 13084
217. West K.A., Castillo S.S., and Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updates 5 (2002) 234-248
218. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23 (2005) 5347-5356
219. Wu C., Wangpaichitr M., Feun L., Kuo M.T., Robles C., Lampidis T., and Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol. Cancer 4 (2005) 25
220. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., and Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62 (2002) 4132-4141
221. Yamamoto S., Tomita Y., Hoshida Y., et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 10 (2004) 2846-2850
222. Yang L., Dan H.C., Sun M., et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64 (2004) 4394-4399
223. Yauch R.L., Januario T., Eberhard D.A., et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11 (2005) 8686-8698
224. Yee K.W., Zeng Z., Konopleva M., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 12 (2006) 5165-5173
225. Yip-Schneider M.T., Wiesenauer C.A., and Schmidt C.M. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J. Gastrointest. Surg. 7 (2003) 354-363
226. Yokomizo A., Tindall D.J., Drabkin H., et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17 (1998) 475-479
227. Yoshimoto M., Cunha I.W., Coudry R.A., et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer 97 (2007) 678-685
228. Yuan Z.Q., Sun M., Feldman R.I., et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19 (2000) 2324-2330
229. Zafar Y., Lager J., Yu D., et al. Preliminary results of a phase I study of bevacizumab in combination with everolimus in patients with advanced solid tumors. J. Clin. Oncol. ASCO Annu. Meet. Proc. 24 Suppl. (2006) 3097
230. L. Cell 87 (1996) 619-628
231. Zhang L., Lee K.C., Bhojani M.S., et al. Molecular imaging of Akt kinase activity. Nat. Med. 13 (2007) 1114-1119
232. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3 (2001) 245-252
233. Zinda M.J., Johnson M.A., Paul J.D., et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate and colon. Clin. Cancer Res. 7 (2001) 2475-2479